<DOC>
	<DOCNO>NCT02490020</DOCNO>
	<brief_summary>Although donation cardiac death ( DCD ) major source renal transplantation China , high incidence rate rejection delay graft function ( DGF ) exist due prolong ischemia time . According previous single center study , mesenchymal stem cell ( MSC ) effect prevent rejection DGF renal transplantation , perspective multicenter control study confirm . This perspective multicenter control study focus clarify key role MSC apply via renal arterial peripheral vein injection , reduce rejection DGF renal transplantation . The investigator establish GMP workshop solid research foundation transplant rejection . This study provide new reasonable way immune induction renal transplantation DCD .</brief_summary>
	<brief_title>A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell ( MSC ) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Study prevention MSC rejection transplantation Age 1860 year indication renal transplantation absolute contraindication renal transplantation donation citizen death first time receive renal transplantation sign informed consent 2 . Study treatment MSC rejection transplantation renal transplantation donation citizen death BPAR contraindication renal biopsy sign informed consent loss followup serious adverse event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>Transplantation Rejection</keyword>
	<keyword>donation cardiac death</keyword>
</DOC>